Related Experiment Videos
Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats
K Sugimoto1, K Sakamoto, A Fujimura
1Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan.
Life Sciences
|January 1, 1997
Summary
Probucol reduces cyclosporin A absorption and peak blood levels after oral administration in rats. However, probucol does not significantly alter cyclosporin A
Area of Science:
- Pharmacokinetics
- Drug Interactions
- Toxicology
Background:
- Cyclosporin A is an immunosuppressant with a narrow therapeutic index.
- Probucol is a lipid-lowering agent.
- Understanding drug interactions is crucial for safe and effective drug use.
Purpose of the Study:
- To investigate the pharmacokinetic interaction between cyclosporin A and probucol.
- To determine the effect of probucol pretreatment on cyclosporin A absorption and disposition.
Main Methods:
- Rats were administered cyclosporin A orally or intravenously, with or without probucol pretreatment.
- Whole blood concentrations of cyclosporin A were measured over time.
- Pharmacokinetic parameters including peak concentration, area under the curve (AUC), and bioavailability were calculated.
Main Results:
- Oral cyclosporin A administration with probucol resulted in a 34% reduction in peak concentration and a 30% decrease in AUC.
- Bioavailability of oral cyclosporin A decreased by 33% with probucol treatment.
- Intravenous administration showed no significant changes in AUC, elimination half-life, or total clearance of cyclosporin A.
Conclusions:
- Probucol may decrease the absorption fraction of orally administered cyclosporin A.
- Probucol does not appear to profoundly influence the overall disposition of cyclosporin A after intravenous administration.
- Coadministration of probucol could impact cyclosporin A efficacy when given orally.